Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer

  • Iliana K. Kerzeli
  • , Alexandros Kostakis
  • , Polat Türker
  • , Per-Uno Malmström
  • , Tammer Hemdan
  • , Artur Mezheyeuski
  • , Douglas G. Ward
  • , Richard T. Bryan
  • , Ulrika Segersten
  • , Martin Lord
  • , Sara M. Mangsbo*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

61 Downloads (Pure)

Abstract

Background: Urothelial bladder cancer is most frequently diagnosed at the non-muscle-invasive stage (NMIBC). However, recurrences and interventions for intermediate and high-risk NMIBC patients impact the quality of life. Biomarkers for patient stratification could help to avoid unnecessary interventions whilst indicating aggressive measures when required.

Methods: In this study, immuno-oncology focused, multiplexed proximity extension assays were utilised to analyse plasma (n = 90) and urine (n = 40) samples from 90 newly-diagnosed and treatment-naïve bladder cancer patients. Public single-cell RNA-sequencing and microarray data from patient tumour tissues and murine OH-BBN-induced urothelial carcinomas were also explored to further corroborate the proteomic findings.

Results: Plasma from muscle-invasive, urothelial bladder cancer patients displayed higher levels of MMP7 (p = 0.028) and CCL23 (p = 0.03) compared to NMIBC patients, whereas urine displayed higher levels of CD27 (p = 0.044) and CD40 (p = 0.04) in the NMIBC group by two-sided Wilcoxon rank-sum tests. Random forest survival and multivariable regression analyses identified increased MMP12 plasma levels as an independent marker (p < 0.001) associated with shorter overall survival (HR = 1.8, p < 0.001, 95% CI:1.3–2.5); this finding was validated in an independent patient OLINK cohort, but could not be established using a transcriptomic microarray dataset. Single-cell transcriptomics analyses indicated tumour-infiltrating macrophages as a putative source of MMP12.

Conclusions: The measurable levels of tumour-localised, immune-cell-derived MMP12 in blood suggest MMP12 as an important biomarker that could complement histopathology-based risk stratification. As MMP12 stems from infiltrating immune cells rather than the tumor cells themselves, analyses performed on tissue biopsy material risk a biased selection of biomarkers produced by the tumour, while ignoring the surrounding microenvironment.
Original languageEnglish
Article number605
Number of pages13
JournalBMC Cancer
Volume23
Issue number1
DOIs
Publication statusPublished - 30 Jun 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Urothelial bladder cancer
  • Proteomics
  • Matrix metalloproteinase 12 (MMP12)
  • Macrophages
  • Single-cell transcriptomics
  • Biomarkers
  • Proximity Extension Assay (PEA)

Fingerprint

Dive into the research topics of 'Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer'. Together they form a unique fingerprint.

Cite this